Search Results: nurture
Biogen Shares Results from Landmark NURTURE Study of Pre-Symptomatic SMA Patients Treated with Spinraza
Biogen, Inc., today announced new results from NURTURE, the longest study of pre-symptomatic patients with spinal muscular atrophy (SMA), which is transforming […]
Read More ›Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with Spinraza Published in Neuromuscular Disorders
Biogen today announced that the journal Neuromuscular Disorders has published data from NURTURE, the first study investigating a treatment targeting the underlying cause of spinal […]
Read More ›Biogen Announces New NURTURE Data at the 2019 Annual SMA Conference
Biogen today announced new results from the NURTURE study, adding data to the longest study of spinal muscular atrophy (SMA) in pre-symptomatic infants (n=25). These […]
Read More ›Biogen Announces New Interim Phase 2 Results From NURTURE
Biogen recently announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA or nusinersen among […]
Read More ›Biogen Releases New Data from Cherish and Nurture Trials
Biogen will present Phase 3 end of study SPINRAZA® (nusinersen) data from CHERISH, which demonstrated a highly statistically significant and clinically meaningful improvement in motor […]
Read More ›Biogen Announces NURTURE, a New Phase 2 Clinical Trial
Biogen, in collaboration with Isis Pharmaceuticals, has announced that they will soon open recruiting for NURTURE. This is a multi-center, Phase 2 clinical study evaluating […]
Read More ›New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
Biogen Inc. announced new SPINRAZA® (nusinersen) data aimed at answering critical questions for the spinal muscular atrophy (SMA) community. The data were presented at the SMA […]
Read More ›Biogen Announces New Updates Across its SMA Research Program at 2023 MDA Conference
First patient treated in the ASCEND study evaluating the potential benefit of investigational higher dose nusinersen in children, teens and adults previously treated with Evrysdi® (risdiplam) […]
Read More ›Clinical Resources
Make today a breakthrough. This page includes resources for clinicians helping to improve quality of care for individuals with spinal muscular atrophy (SMA). Quick Links […]
Read More ›Spinraza®
Spinraza® Spinraza® was the first FDA-approved therapy to treat spinal muscular atrophy (SMA). It is an SMN-enhancing therapy that works by targeting the SMN2 gene, […]
Read More ›